IR-Releases
We will keep you informed. Here you find our Ad-hoc-Releases and our releases respective to the capital markets.
|
|
|
Dividend proposal of 4% for members Operating result at €280.4 million declines as expected due to special effects Reduction in structured financial products of over €1 billion ...
|
| |
|
|
The rating agency Standard & Poor's (S&P) has raised apoBank's ratings to AA- (previous: A+) and A-1+ (previous: A-1) as part of the initial adoption of its new rating methodology ...
|
| |
|
|
The rating agency Standard & Poor's (S&P) published the annual update of its rating analysis to apobank. In this analysis S&P confirms apoBank's rating on a good level with ...
|
| |
|
|
Net profit on previous year's level at €23.5 million Growth in core business: further increases in lending and deposit business IT migration costs impact on operating result Forecast ...
|
| |
|
|
In the course of focussing on its core business, Deutsche Apotheker- und Ärztebank (apoBank) parts with its shareholding in AC Capital Partners Ltd (AC Capital) as previously announced. ...
|
| |
|
|
Net profit of €53.4 million allows for a 4% dividend Operating result up 7% to €341.0 million Burdens from financial instruments portfolio reduced significantly Plans to continue ...
|
| |
|
|
Eckhard Lüdering appointed Risk Director Bernd Span leaves apoBank on mutual agreements The Supervisory Board of Deutsche Apotheker- und Ärztebank (apoBank) has made the following ...
|
| |
|
|
The Supervisory Board of Deutsche Apotheker- und Ärztebank (apoBank) appointed Harald Felzen to the Board of Directors of the Düsseldorf based institution, announced Hermann ...
|
|
|
Über die apoBank
